RSV Vaccines Need Multiple Animal Models Before Infant Testing, Panel Says
Executive Summary
US FDA's advisors want data from three animal models – not just the cotton rats that Janssen was hoping for – before candidate vaccines are tested in healthy infants.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
FDA Panel To Weigh Animal, Adult Human Data For Initiation Of RSV Vaccine Trials In Infants
Sponsors have been increasingly developing vaccine candidates for the respiratory syncytial virus with an unmet need existing for infants; the advisory committee will evaluate FDA's proposed approach for developing candidates in the target population.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.